Scholarlink

<p>It is unclear to what extent genetic risk offsets the protective effects of better premorbid cognitive health on the risk of Alzheimer’s disease (AD). We tested for associations between measures of premorbid cognitive health, apolipoprotein (<i>APOE</i>) e4 ‘risk’ genotype, and their interaction, with risk of incident AD and age of diagnosis, in UK Biobank participants aged ≥55 years at baseline, adjusted for potential confounders. During follow-up, 3,505/252,340 (1.39%) participants received an incident diagnosis of AD. There were significant associations between better performance on each cognitive test with lower risk of incident AD, and later age at diagnosis. However, the benefit of better baseline cognitive scores on AD risk was significantly attenuated in <i>APOE</i> e4 carriers. These data demonstrate that the association between premorbid cognitive health and subsequent risk of AD is influenced by <i>APOE</i> e4 genotype. This has implications for risk stratification and targeted intervention.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Associations and interactions between premorbid cognitive health, apolipoprotein e4 genotype, and incident Alzheimer’s disease in UK Biobank (N = 252,340)

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年6月18日

查看全文
  • Mohammad A. Jareebi,
  • Josie Fullerton,
  • Angelina K. Kancheva,
  • Rachana Tank,
  • Lachlan Gilchrist,
  • Emma R. Russell,
  • Laura M. Lyall,
  • Joey Ward,
  • Jana J. Anderson,
  • Rona J. Strawbridge,
  • Terry Quinn,
  • William Stewart,
  • Ian J. Deary,
  • Simon R. Cox,
  • Donald M. Lyall

摘要

It is unclear to what extent genetic risk offsets the protective effects of better premorbid cognitive health on the risk of Alzheimer’s disease (AD). We tested for associations between measures of premorbid cognitive health, apolipoprotein (APOE) e4 ‘risk’ genotype, and their interaction, with risk of incident AD and age of diagnosis, in UK Biobank participants aged ≥55 years at baseline, adjusted for potential confounders. During follow-up, 3,505/252,340 (1.39%) participants received an incident diagnosis of AD. There were significant associations between better performance on each cognitive test with lower risk of incident AD, and later age at diagnosis. However, the benefit of better baseline cognitive scores on AD risk was significantly attenuated in APOE e4 carriers. These data demonstrate that the association between premorbid cognitive health and subsequent risk of AD is influenced by APOE e4 genotype. This has implications for risk stratification and targeted intervention.